StockMarketWire.com - PureTech Health noted that independent affiliate resTORbio had announced disappointing data from a study evaluating the safety and efficacy of a treatment for clinically symptomatic respiratory illness.

The company will continue development of the treatment -- RTB101 -- in other aging-related diseases, including Parkinson's disease.

In the study, the treatment did not meet its primary endpoint and resTORbio said that it had stopped the development of RTB101 in this indication.

'While we are disappointed in these results, there are extensive preclinical data supporting the potential therapeutic benefit of TORC1 inhibition in multiple aging-related diseases, including Parkinson's disease, for which we have an active Phase 1b/2a trial of RTB101 alone or in combination with sirolimus," chief executive Chen Schor said.

At 2:22pm: [LON:PRTC] PureTech Health Plc share price was -14p at 228p



Story provided by StockMarketWire.com